WHAT DO WE KNOW?
Congenital disorders of glycosylation (CDG) are a family of complex metabolic diseases. Known CDG population is mostly pediatric. COVID-19 is a newly identified virus causing flu-like and respiratory infection (and, in severe cases pneumonia) symptoms. Less frequently, gastrointestinal manifestations (e.g. diarrhea) may occur. Although data is still scarce, some vulnerable (“high risk”) populations have been identified, namely: older adults, patients with lung, heart conditions and/or diabetes.
A very recent update from the Centres for Disease Control (CDC) has stated that NEUROLOGIC DISEASES and NEURODEVELOPMENTAL CONDITIONS may have an increased risk of having serious COVID-19 infection-related manifestations.
STATEMENT ON COVID-19
Updated on 19th of March 2020
This is a GLOBAL recommendation.
COVID-19 outbreak prevalence and response measures vary across countries.
STATEMENT ENDORSED BY:
Dr. Eva Morava
Dr. Rita Barone
University Hospital of Catania
Dr. Mercedes Serrano
Hospital Sant Joan de Dèu
Dr. Jaak Jaeken
University Hospitals Leuven
Dr. David Coman
Dr. Ruqaiah Altassan
Dr. Laia Alsina
Hospital Sant Joan de Dèu, Barcelona
Dr. Andrew Edmonson
Children’s Hospital of Philadelphia
Dr. Christima Lam
University of Washington and Seattle Children’s Hospital
Dr. Stephanie Grunewald
Dr. Erik Eklund
Skane University Hospital and Lund University
Dr. Mari-Anne Vals
Tartu University Hospital Children’s Clinic
Dr. Jolanta Sykut-Cegielska
The Institute of Mother and Child
Dr. Bradley S. Miller
University of Minnesota Masonic Children’s Hospital
Frontiers in CDG Consortia (FCDGC)
CDG & Allies – Professionals and Patient associations International Network (CDG&Allies-PPAIN)
MetabERN – European Reference Network for Rare Metabolic Diseases
National Institute of Children´s Diseases (Národný Ústav Detských Chorôb), Bratislava, Slovakia
The Portuguese Association for CDG (APCDG)
CDG The Netherlands (VKS)
Asociación Española CDG (AESCDG)
Les P’tits CDG
Amour Fund (USA)